Temozolomide + Thalidomide

From OncoWiki
Revision as of 01:39, 3 May 2008 by Palmdoc (talk | contribs) (→‎Indication)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigationJump to search

Indication

Metastatic cancer

  • Temozolomide (Temodar) 75 mg/m2 po qd x 6 wks every 8 wks
  • Thalidomide (Thalomid) 100-400 mg po qd
  • Thalidomide is classified as an immunomodulatory agent, and an antiangiogenic agent.

References

Hwu WJ et al. Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J Clin Oncol 2003; 21:3351